Cost Curve
everything drug pricing and policy, every day
Connect
It's a brief one today, with a bit on the California 340B measure but not much else
It's Election Day. Please vote. And then you should probably unplug. Maybe watch some hockey. That's my plan, anyway.
And a new analysis finds that even it were legal to use Bayh-Dole march-in rights to control drug prices (and it's almost certainly not), there aren't even that many drugs that would qualify
And pharma execs are all over 340B during this earnings season
There are a couple of interesting nuggets in earnings and elsewhere, but the impending election has created a dull roar of content that can mostly be ignored
Plus looking at last week's 340B poll and flagging that tomorrow is red-letter day for IRA lawsuits
Plus the head of the PBM lobby gets the attention of WaPo
And PBM commentary from Georgia pharmacists, Blue Shield of California, Mark Cuban, and others
Plus links on accumulators and the prospects for the lame-duck session
And JAMA offers a clip-n-save piece on ways consumers can find cheaper meds
Plus the NYT published the second piece in its PBM series, showing how the middlemen are killing pharmacies
I know, I know. It's a Saturday. Pardon the interruption.
